Context Adrenal hyperfunction is associated with an increased risk of cardiometabolic complications in subjects with adrenal incidentaloma (AI). Reliable prevalence estimates of functioning AIs are important to direct resources allocations. Objective To assess the prevalence of autonomous/possible autonomous cortisol secretion (ACS), primary aldosteronism (PA), pheochromocytoma (PHEO), and Cushing syndrome (CS) in patients with AI. Methods We performed a comprehensive search of multiple databases (PubMed, Ovid MEDLINE, Web of Science) for potentially relevant studies without language restriction, up to February 2022. Of the 1661 publications evaluated at title and abstract levels, 161 were examined as full text and 36 were included. Study level clinical data were extracted by 3 independent reviewers. Results The overall prevalence of functioning AIs was 27.5% (95% CI 23.0, 32.5). ACS/possible ACS, with a prevalence of 11.7% (95% CI 8.6, 15.7), was the most frequent hormonal alteration, while PA occurred in 4.4% of the patients (95% CI 3.1, 6.2). Subgroup analysis showed that PA was more prevalent in patients from Asia than in patients from Europe/America; in contrast, ACS/possible ACS had a lower prevalence in Asian countries. At meta-regression analysis, the prevalence of ACS/possible ACS was influenced by the proportion of female patients, while the prevalence of PA was positively associated with the proportion of patients with hypertension and the publication year. Finally, PHEO and CS prevalence were 3.8% (95% CI 2.8, 5.0) and 3.1% (95% CI 2.3, 4.3) respectively. Conclusion This meta-analysis provides extensive data on the prevalence of functioning AIs and the factors affecting heterogeneity in prevalence estimates.
Prevalence of Functioning Adrenal Incidentalomas: A Systematic Review and Meta-analysis
Sconfienza, ElisaFirst
;Tetti, Martina;Forestiero, Vittorio;Veglio, Franco;Mulatero, Paolo;Monticone, Silvia
Last
2023-01-01
Abstract
Context Adrenal hyperfunction is associated with an increased risk of cardiometabolic complications in subjects with adrenal incidentaloma (AI). Reliable prevalence estimates of functioning AIs are important to direct resources allocations. Objective To assess the prevalence of autonomous/possible autonomous cortisol secretion (ACS), primary aldosteronism (PA), pheochromocytoma (PHEO), and Cushing syndrome (CS) in patients with AI. Methods We performed a comprehensive search of multiple databases (PubMed, Ovid MEDLINE, Web of Science) for potentially relevant studies without language restriction, up to February 2022. Of the 1661 publications evaluated at title and abstract levels, 161 were examined as full text and 36 were included. Study level clinical data were extracted by 3 independent reviewers. Results The overall prevalence of functioning AIs was 27.5% (95% CI 23.0, 32.5). ACS/possible ACS, with a prevalence of 11.7% (95% CI 8.6, 15.7), was the most frequent hormonal alteration, while PA occurred in 4.4% of the patients (95% CI 3.1, 6.2). Subgroup analysis showed that PA was more prevalent in patients from Asia than in patients from Europe/America; in contrast, ACS/possible ACS had a lower prevalence in Asian countries. At meta-regression analysis, the prevalence of ACS/possible ACS was influenced by the proportion of female patients, while the prevalence of PA was positively associated with the proportion of patients with hypertension and the publication year. Finally, PHEO and CS prevalence were 3.8% (95% CI 2.8, 5.0) and 3.1% (95% CI 2.3, 4.3) respectively. Conclusion This meta-analysis provides extensive data on the prevalence of functioning AIs and the factors affecting heterogeneity in prevalence estimates.File | Dimensione | Formato | |
---|---|---|---|
#jc.2022-02020_Manuscript_postprint.docx
Open Access dal 02/07/2024
Descrizione: Manuscript
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
85.84 kB
Formato
Microsoft Word XML
|
85.84 kB | Microsoft Word XML | Visualizza/Apri |
Figure 1.pdf
Open Access dal 02/07/2024
Descrizione: Figure 1
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
12 kB
Formato
Adobe PDF
|
12 kB | Adobe PDF | Visualizza/Apri |
Figure 3.pdf
Open Access dal 02/07/2024
Descrizione: Figure 3
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
30.68 kB
Formato
Adobe PDF
|
30.68 kB | Adobe PDF | Visualizza/Apri |
Figure 4.pdf
Open Access dal 02/07/2024
Descrizione: Figure 4
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
29.65 kB
Formato
Adobe PDF
|
29.65 kB | Adobe PDF | Visualizza/Apri |
Figure 5.pdf
Open Access dal 02/07/2024
Descrizione: Figure 5
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
29.76 kB
Formato
Adobe PDF
|
29.76 kB | Adobe PDF | Visualizza/Apri |
Figure 6.pdf
Open Access dal 02/07/2024
Descrizione: Figure 6
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
29.24 kB
Formato
Adobe PDF
|
29.24 kB | Adobe PDF | Visualizza/Apri |
#jc.2022-02020_Online Supplement_postprint.docx
Open Access dal 02/07/2024
Descrizione: Supplementary file
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
2.32 MB
Formato
Microsoft Word XML
|
2.32 MB | Microsoft Word XML | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.